Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals

Yahoo Finance • 4 days ago

Arrowhead Pharmaceuticals to Present New Clinical Data at the European Society of Cardiology Congress

- Detailed results from the Phase 3 SHASTA-3 and SHASTA-4 Studies of Plozasiran in Patients with Severe Hypertriglyceridemia will be presented as a HOT LINE Late-Breaking Science Session on August 30, 2026 - - Arrowhead will host a webcas... Full story

Yahoo Finance • 24 days ago

Arrowhead Pharmaceuticals Inc (ARWR) (Q3 2026) Earnings Call Highlights: Strong Phase III Data ...

This article first appeared on GuruFocus. Net Loss: $194.3 million, or a loss of $1.36 per share, for the fiscal 2026 third quarter ended June 30, 2026. Revenue: Approximately $75 million for the quarter, up from $28 million in the prior... Full story

Yahoo Finance • last month

The 'Best-Case Scenario' That Shot Arrowhead Stock Sky-High

Arrowhead Pharmaceuticals' triglycerides-buster hit the "best-case scenario" in two studies Wednesday, leading the stock to skyrocket. Continue Reading... Full story

Yahoo Finance • last month

Ionis drops as Arrowhead posts late-stage trial win for lipid-lowering drug

[Up Down Arrows. Green And Red Color] Arrowhead Pharmaceuticals (ARWR [https://seekingalpha.com/symbol/ARWR]) on Wednesday announced a late-stage trial win for its lipid-lowering agent plozasiran in patients with severe hypertriglyceridem... Full story

Yahoo Finance • 2 months ago

Can Biogen Convince Skeptics That Cutting a Rogue Protein Slows Alzheimer’s?

Biogen will present detailed Phase 2 study data for its experimental Alzheimer’s drug diranersen at a conference in London. Continue Reading... Full story

Yahoo Finance • 2 months ago

3 Under-the-Radar Biotech Takeover Targets for the Next Pharma Buying Spree

Quick Read Crinetics Pharmaceuticals leads as the cleanest buyout candidate at $3.79 billion; Cytokinetics' FDA-approved Myqorzo attracts Bristol Myers Squibb or Novartis but costs $10.86 billion. ARWR's ARO-INHBE nearly doubled tirzepati... Full story

Yahoo Finance • 4 months ago

Arrowhead (ARWR) Rated Buy on Metabolic Pipeline Potential

Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) ranks among the most profitable biotech stocks to buy now. Following comments on Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR)’s obesity and metabolic illness initiatives, TD Cowen reiterated its... Full story

Yahoo Finance • 4 months ago

Complement Inhibitors Market Outlook Remains Strong During the Forecast Period (2026–2036) with Increasing Adoption of C5 and C3 Targeted Drugs | DelveInsight

DelveInsight Business Research LLP The complement inhibitors market is projected to grow, driven by the rising prevalence of complement-mediated diseases, intensified R&D efforts, and biotechnological advancements enabling novel therapeut... Full story

Yahoo Finance • 4 months ago

Stocks Erase Early Gains as Crude Prices Jump on Iran Concerns

The S&P 500 Index ($SPX) (SPY) today is down -0.13%, the Dow Jones Industrial Average ($DOWI) (DIA) is down -0.13%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +0.02%.  June E-mini S&P futures (ESM26) are down -0.13%, and June E-mini Nasd... Full story

Yahoo Finance • 5 months ago

Arrowhead (ARWR) FQ1 2026 Revenue Hits $264M as REDEMPLO Approval Marks Commercial Shift

Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) is one of the best multibagger stocks to invest in according to billionaires. On February 5, Arrowhead Pharmaceuticals achieved a strategic turning point in FQ1 2026, transitioning into a commer... Full story

Yahoo Finance • 7 months ago

Arrowhead price target lowered to $78 from $81 at Morgan Stanley

Morgan Stanley lowered the firm’s price target on Arrowhead (ARWR) to $78 from $81 and keeps an Equal Weight rating on the shares. Broad pipeline execution continues with multiple readouts expected later this year, including key Phase 3 SH... Full story

Yahoo Finance • 7 months ago

Arrowhead outlines pivotal 2026 milestones with REDEMPLO launch, $1.33B capital boost, and robust cardiometabolic pipeline

Earnings Call Insights: Arrowhead Pharmaceuticals (ARWR) Q1 2026 MANAGEMENT VIEW * Dr. Christopher Anzalone, Chairman, CEO & President, stated, "We had another quarter of strong execution across all areas of our business, and we are we... Full story

Yahoo Finance • 7 months ago

Arrowhead Pharmaceuticals Inc (ARWR) Q1 2026 Earnings Call Highlights: Strong Financial ...

This article first appeared on GuruFocus. Net Income: $30.8 million for the quarter ended December 31, 2025. Earnings Per Share (EPS): $0.22 per share based on 140.7 million fully diluted weighted average shares outstanding. Revenue: $264... Full story

Yahoo Finance • 7 months ago

Arrowhead Research: Fiscal Q1 Earnings Snapshot

PASADENA, Calif. (AP) — PASADENA, Calif. (AP) — Arrowhead Research Corp. (ARWR) on Thursday reported fiscal first-quarter net income of $30.8 million, after reporting a loss in the same period a year earlier. The Pasadena, California-base... Full story

Yahoo Finance • 7 months ago

Ciena Set to Join S&P 500; Arrowhead Pharmaceuticals to Join S&P MidCap 400; ADT and OneSpaWorld Holdings to Join S&P SmallCap 600

NEW YORK, Feb. 4, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400, S&P SmallCap 600: S&P MidCap 400 constituent Ciena Corp. (NYSE: CIEN) will replace Dayforce Inc. (NYSE: DAY) in t... Full story

Yahoo Finance • 7 months ago

Arrowhead Stock Has Skyrocketed 290% in One Year, and One Fund Trimmed Its Holdings by $4 Million

Privium Fund Management reported a sale of 75,747 shares of Arrowhead Pharmaceuticals(NASDAQ:ARWR) in a February 2 SEC filing, with the estimated trade value at $3.71 million based on quarterly average pricing. What happened According to... Full story

Yahoo Finance • 8 months ago

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

PASADENA, Calif., December 15, 2025--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on December 12, 2025, the Company’s Board of Directors... Full story

Yahoo Finance • 9 months ago

Arrowhead Pharmaceuticals gets FDA Breakthrough Therapy status for plozasiran

[Omega 3 fatty acid molecules] piyaset/iStock via Getty Images * Arrowhead Pharmaceuticals, Inc. (ARWR [https://seekingalpha.com/symbol/ARWR]) has announced that the FDA has given Breakthrough Therapy designation to its investigational... Full story

Yahoo Finance • 9 months ago

How Do Sarepta (SRPT)’s Enhanced Safety Moves Reflect Its Approach to Long-Term Risk Management?

Earlier this week, Sarepta Therapeutics received FDA approval to begin dosing non-ambulant Duchenne muscular dystrophy patients in Cohort 8 of the ENDEAVOR study, evaluating an enhanced immunosuppression regimen with Elevidys, and announce... Full story

Yahoo Finance • 9 months ago

Sector Update: Health Care Stocks Softer Late Afternoon

Health care stocks were lower late Wednesday afternoon, with the NYSE Health Care Index easing 0.1% PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium... Full story